The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Bringing Products to Market.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

Veriheal

AUGUST 28, 2023

This discovery adds to the ongoing research on the medical use of psychedelics in psychiatry. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. cm fine sawdust.”

Treatment 63

Treatment Clinical Trials Therapy Research and Development 63

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. . – December 16, 2021) – Entheon Biomedical Corp. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle. .

DEA 111

DEA Research and Development Clinical Trials Cannabis 111

Cannabis Law Report

SEPTEMBER 22, 2021

Despite this, the Home Office “fails to act, perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG), of which Mr Blunt is chairman. The first part of their review was published in July and the second part of the work is now underway.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline. About AXIM® Biotechnologies.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

NOVEMBER 19, 2021

“These patent filings are critical components of PsyBio’s corporate development strategy. “These patent filings are critical components of PsyBio’s corporate development strategy. PsyBio remains interested in developing the intellectual property landscape within the psycho-targeted development drug arena.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

MMJ Recs

MAY 9, 2024

The proposed legislation seeks to amend existing laws and policies to allow VA healthcare providers to discuss medical marijuana with patients, conduct research on its efficacy, and prescribe medical cannabis in states where it is legal. Any questions related to research can be addressed to VHABLRD-CSRD@va.gov.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. The full statement. Nair, Ph.D., Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “At At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

MARCH 18, 2020

The company, a leader in hemp-derived CBD extract products, has created an internal research and development division led by a former healthcare executive to focus on the science of hemp-derived phytocannabinoids, terpenes and flavonoid compounds. Charlotte’s Web Holdings, Inc. CW Labs and have an additional office in Boulder, Colo.

Clinical Trials 59

Clinical Trials Research and Development Terpenes Hemp 59

Cannabis Law Report

AUGUST 5, 2021

NEO:FH , Forum ), an exclusively natural psychedelic drug development company. Filament Health has been developing the technology in order to extract and standardize a stable dose of natural psilocybin to surpass crop-to-crop and flush-to-flush variability. In comes companies like Filament Health Corp. Investment summary.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JUNE 21, 2021

(OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. NEO: MYCO) plans to leverage AI and ML to accelerate its research and development. Industry Developments.

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. RYAH’s database provides that type of scale to all parties involved – patients, doctors, researchers, drug developers, growers, etc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. The efficacy of such products has not been confirmed by approved research.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We The Maya platform empowers psychedelic researchers, providers, and participants to collectively chart psychedelic best practices.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. While psychedelic therapies make their way through the drug development pipeline, seven U.S.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Phase 2 trial underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ).

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing. Parkinson’s disease and cannabis. The effectiveness of cannabis for Parkinson’s disease.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JANUARY 19, 2022

During his 24 years in Congress, Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility. About IGC: India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

The Cannigma

DECEMBER 14, 2021

HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant. There are no published studies on the efficacy or safety of HHC in human subjects but that has not stopped some manufacturers from producing and selling HHC products. Is HCC safe for humans?

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

PrestoDoctor

OCTOBER 11, 2023

One area of research that has been gaining attention is the use of CBD-rich cannabis in treating the social symptoms of Autism Spectrum Disorder (ASD). Some individuals may have delayed speech development or struggle with expressing their thoughts and emotions effectively. For years, the use of cannabis has been a controversial topic.

CBD 52

CBD Research and Development Clinical Trials Treatment 52